Floatz logo

Tagitanlimab

ER+HER2- Breast Cancer

West China Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

890 Active assets in the ER+HER2- Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

Tagitanlimab is also rated in:

prostate adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Prostate Adenocarcinoma With Neuroendocrine DifferentiationDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →